XYF19 CAR-T cell therapy

XYF19 CAR-T cell therapy is an autologous, CRISPR-edited anti-CD19 chimeric antigen receptor T-cell product in early clinical development for B-cell malignancies, particularly adult relapsed/refractory B-cell acute lymphoblastic leukemia and CD19-positive leukemias and lymphomas. The therapy uses a lentiviral vector to transduce a CD19-specific CAR into a patient’s own T cells and employs CRISPR/Cas9 editing to decrease expression of hematopoietic progenitor kinase 1 (HPK1), an intracellular negative regulator of T-cell receptor signaling, thereby enhancing antitumor activity while aiming to reduce cytokine release syndrome and neurotoxicity.[2][3][5][7][9][10][12] Upon infusion, XYF19 CAR-T cells recognize and bind CD19-overexpressing B-cell tumor cells, leading to their activation, proliferation, cytokine release, and cytotoxic killing of malignant cells, with early phase I data showing high complete remission rates and a favorable safety profile compared with earlier-generation CD19 CAR-T therapies.[2][4][7][8][10][12]

Other names

Autologous CRISPR-edited anti-CD19 CAR T cells XYF19XYF19 CAR-T cellsXYF-19 CAR-T cellsXYF 19 CAR-T cellsCRISPR (HPK1) edited CD19-specific CAR-T cells XYF19